Skip to main navigation

About
R&D
Pipeline
Investors & Media
Careers

Investors & Media

Overview
News
Events & Presentations
Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
- FAQs
- Investor Contact

News

Year

June 7, 2021

NGM Bio to Present at Two Upcoming Investor Conferences

May 24, 2021

NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH

May 23, 2021

NGM Bio to Host Conference Call to Discuss Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH

May 6, 2021

NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results

April 28, 2021

NGM Announces Nomination of Roger M. Perlmutter for Election to Its Board of Directors

March 4, 2021

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2020 Financial Results

March 2, 2021

NGM Bio Initiates Expansion of Ongoing Phase 1b Proof-of-Concept Study of NGM120 in Patients with Metastatic Pancreatic Cancer

February 25, 2021

NGM Bio to Present at the Cowen 41st Annual Health Care Conference

February 9, 2021

NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

January 12, 2021

NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Toolkit

© 2021 NGM Biopharmaceuticals.

All Rights Reserved.

Privacy Policy.

Top